Twist Bioscience Corp. and its CEO must defend against allegations that they at least recklessly misled investors with statements about synthetic DNA quality and automated manufacturing.
The benefits fund leading the case sufficiently pleaded CEO Emily Leproust‘s knowledge of product issues and customer qualms in “hundreds” of gatherings based on former employees’ accounts—including one confidential witness’ claim of being asked to avoid meetings for raising problems—Judge Eumi K. Lee said.
But the Policemen’s Annuity and Benefit Fund of Chicago didn’t similarly allege former chief financial officer Jim Thorburn‘s state of mind for securities fraud on the biotech company’s ...
Learn more about Bloomberg Tax or Log In to keep reading:
Learn About Bloomberg Tax
From research to software to news, find what you need to stay ahead.
Already a subscriber?
Log in to keep reading or access research tools.